【レポートの概要（一部）】
1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials
3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026
4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026
5.1 Market Overview, 2016
5.2 Leading ADCs in 2016
5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
5.4.1 Competition for Leading Drugs Will Restrain Growth
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
5.5.1 Adcetris: Sales 2011-2015
5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.5.4 Adcetris Sales Forecast 2016-2026
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Mixed Results from Different Clinical Trials
5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
5.6.3 Kadcyla Sales Forecast 2016-2026
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounted for Over 50% of the Pipeline in 2015
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.1.1 Granted Breakthrough Therapy Designation
5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026
6.1 Defining an ‘Engineered Antibody’
6.2 Market Overview 2016, and the Leading Engineered Antibodies
6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo Sales Forecast 2016-2026
6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva Receives Second Approval
6.6.4 Gazyva Sales Forecast 2016-2026
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026
7.1 Bispecific Antibodies: Market Overview, 2016
7.2 Bispecific Antibodies: Market Forecast 2016-2026
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2016-2026
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
7.5.2 Blincyto: Sales Forecast 2016-2026
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026
8.1 Antibody Fragments and ALPs: Market Overview, 2016
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
8.4.1 Kalbitor: Sales Forecast 2016-2026
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2016-2026?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
8.7.1 Caplacizumab (anti-vWF, Ablynx)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.8.4 ESBA1008 (anti-VEGF, Novartis)
8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.9.2 ALX-0171 (anti-respiratory syncytial virus)
8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2016-2026
9.1 Biosimilar Antibodies: Market Overview, 2016
9.2 Leading Biosimilar Antibodies in 2016.
9.3 Biosimilar Antibodies: Market Forecast 2016-2026
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
9.4.2 Rising Incidence of Cancer will Drive Demand
9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths: The Path Towards Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2016-2026
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
11.2.1 arGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 arGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for arGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2026
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
12.2 Current Status of the Market and Leading Segments
12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
12.4 Leading Regional Markets
12.5 Development of the Market to 2026
12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
12.7 Most Developers Continue to Target Cancer
12.8 Strategies for Growth in 2016-2026
【レポート販売概要】
■ タイトル：次世代抗体治療の世界市場予測2016-2026■ 英文：Next-Generation Antibody Therapies Market Forecast 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN60630
■ 調査対象地域：グローバル
- 頭頸部癌：世界の臨床試験レビュー（2014年上半期）Head And Neck Carcinoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Head And Neck Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Head And Neck Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Head And Neck Carcinoma. It includes an overview of the trial numbers …
- 非接触型ICカードの世界市場2016-2020About Contactless Smart Cards Smart cards are pocket-sized cards that are embedded with integrated circuits. These smart cards can be used for individual identification and authentication by organizations in various sectors, including banking, financial services, and insurance (BFSI); transportation; government; and healthcare. Furthermore, these smart cards can be used by enterprises to provide a …
- プログラマブルロボットの世界市場予測Programmable robot is an automatic device that performs functions normally ascribed though programs or remote control. These can range from remote-controlled to PC-controlled robots and also from simple wheeled robots to complex robots such as humanoids. These robots help in understanding and conceptualizing the theories involved in designing and operating a robot and also help to program the robo …
- 射出成形機の世界市場：製品タイプ別（プラスチック、ゴム、金属、セラミック）、機械の種類別（油圧式射出成形機、全電動式射出成形機、ハイブリッド式射出成形機）、型締力別（0～200トン、201～500トン、201トン以上）、最終用途産業別、地域別予測Global Injection Molding Machine Market to reach USD 20.9 billion by 2025. Global Injection Molding Machine Market valued approximately USD 16 billion in 2016 is anticipated to grow with a healthy growth rate of more than 3 % over the forecast period 2017-2025 The growth of the market is driven by the high demand from the packaging industry, rising demand for energy saving, growing automotive indu …
- 自動車ウインドシールドの世界市場予測（～2025年）：合わせガラス、強化ガラスThe automotive industry is one of the key contributors to the overall GDP of the world and is growing significantly over the years. Growing economy and improving demographics have surged the demand for vehicles across the globe. As the demand for vehicles is growing, the demand for automotive components is also increasing significantly, especially in countries such as China and India. Also, new ve …
- 臨床検査情報システム（LIS）の世界市場予測（～2024年）“The laboratory information systems market is projected to grow at a CAGR of 6.3% during the forecast period.” The laboratory information systems (LIS) market is projected to reach USD 2.4 billion by 2024 from USD 1.8 billion in 2019, at a CAGR of 6.3%. The need for laboratory automation and increased lab efficiency, development of integrated LIS, the need to comply with regulatory requirements, a …
- Vector Limited：石油・ガスバリューチェーン分析レポート2013Vector Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Vector Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Vector Limited”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the company’s …
- インキ溶剤の世界市場：アルコール、アセテート、炭化水素系溶剤The report covers the global ink solvents market and further segments the market on the basis of chemistry type, product type, process, application, and region. The market data for these types is given with respect to volume (kilotons) and value ($million). The global market value of ink solvents is estimated to be around $827.24 million in 2014 and is projected to grow at a CAGR of more than 5% b …
- ベビーフード及び飲料の世界市場：ミルク、乾燥ベビーフード、調理済み食品The baby food industry is one of the fastest growing segments in the global food market. We forecast the global baby food and drink market will reach a value $55.05bn in 2015. Once the fastest growing segment in the developed markets of North America and Europe, today, the industry is booming in Asia-Pacific, MEA and Latin America. This has been significantly prompted by the growing number of wome …
- レジデンシャルゲートウェイ（RGW）の世界市場2015-2019About residential gateway A residential gateway acts as a mediator between digital home networks and access providers. It helps in combining and connecting the various functions of modems, routers, and wireless access points to a single device such as a laptop, desktop, or tablet. Residential gateway provides remote deployment of Internet services, thus, assuring easy access to multiple networks t …
- Huntington’s Disease：グローバル臨床試験レビューH2, 2013Huntington's Disease Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Huntington's Disease Global Clinical Trials Review, H2, 2013" provides data on the Huntington’s Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Huntington’s Disease. It includes an overview of the trial numbers and their r …
- 短距離防空（SHORAD）ミサイルシステムの世界市場2016-2020About SHORAD Missile SystemShort Range Air Defense (SHORAD) missile system is a weapon or technology that involves detection, tracking, interception, and destruction of attacking short-range missiles. Originally, ADMS was used as a defense against nuclear-armed and intercontinental ballistic missiles (ICBMs); however, its application has widened to defense against short-ranged non-nuclear tactical …
- 世界のペンタエリトリトール（Pentaerythritol）市場（2014-2018）About Pentaerythritol Pentaerythritol is an alcohol with four hydroxyl groups. It is manufactured using formaldehyde and acetaldehyde through the aldol condensation process, which is followed by a crossed Cannizzaro reaction. Pentaerythritol is used in various applications such as alkyd paints, inks, varnishes, adhesives, sealants, and plasticizers. TechNavio's analysts forecast the Global Pentaer …
- 電池リサイクルの世界市場2017-2021About Battery Recycling Battery recycling is a process that aims at diminishing the number of batteries being disposed of as municipal solid waste. Batteries consist of several heavy metals and toxic chemicals. Therefore, disposing of them as regular trash has raised concerns about water pollution and soil contamination. The soil and water pollution caused by the disposal of batteries as a municip …
- 世界の人工甘味料市場2015The Global Artificial Sweeteners Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Artificial Sweeteners industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Artificial Sweeteners market analysis is provided for the international markets including deve …
